AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 22917598 — intervention group
Group type: EXPERIMENTAL
Intervention: Faith-based intervention
Number of subjects: 450
Study 22917598 — intervention group
Group type: EXPERIMENTAL
Intervention: Non-faith based intervention
Number of subjects: 450
Study 22917598 — intervention group
Group type: COMPARATOR
Intervention: Information only control group
Number of subjects: 450
Study 20464583 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan (F) 2.5 mg
Number of subjects: 133
Study 20464583 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan (Z) 2.5 mg
Number of subjects: 133
Study 20464583 — intervention group
Group type: EXPERIMENTAL
Intervention: Frovatriptan (F)
Number of subjects: 133
Study 20464583 — intervention group
Group type: COMPARATOR
Intervention: Zolmitriptan (Z)
Number of subjects: 133
Study 18580852 — intervention group
Group type: COMPARATOR
Intervention: TaqI A polymorphism of the DRD2 gene
Number of subjects: 119
Study 18580852 — intervention group
Group type: COMPARATOR
Intervention: Atypical genotypes of the DAT1 gene
Number of subjects: 119
Study 18580852 — intervention group
Group type: EXPERIMENTAL
Intervention: M235 polymorphism of the angiotensinogene gene
Number of subjects: 119
Study 18580852 — intervention group
Group type: EXPERIMENTAL
Intervention: Neuropsychological tests
Number of subjects: 119
Study 16003228 — intervention group
Group type: EXPERIMENTAL
Intervention: Mycophenolate mofetil (MMF) 1.5 g administered twice daily with CNI dose reduction or discontinuation (group 1: discontinuation, group 2: 50% reduction)
Number of subjects: 27
Study 16003228 — intervention group
Group type: COMPARATOR
Intervention: Control group (CNI dose reduction or discontinuation without MMF)
Number of subjects: 27
Study 12534449 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin (20 mg day-1)
Number of subjects: 64
Study 12534449 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (10 mg day-1)
Number of subjects: 64
Study 12534449 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvastatin (40 mg day-1)
Number of subjects: 64
Study 12534449 — intervention group
Group type: EXPERIMENTAL
Intervention: Pravastatin (40 mg day-1)
Number of subjects: 64
Study 10321660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ramp slope T 0.1 (0.1 secs)
Number of subjects: 12
Study 10321660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ramp slope T 1.5 (1.50 secs)
Number of subjects: 12
Study 10321660 — intervention group
Group type: EXPERIMENTAL
Intervention: Pressure ramp slope values (T 0.1 to T 1.5)
Number of subjects: 12
Study 8542860 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 10 seconds
Number of subjects: 100
Study 8542860 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 20 seconds
Number of subjects: 100
Study 8542860 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 30 seconds
Number of subjects: 100
Study 8542860 — intervention group
Group type: EXPERIMENTAL
Intervention: Injection speed of 1 minute (added group)
Number of subjects: 100
Study 1787659 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane (0.5 vol.%) and nitrous oxide (65 vol.%) anesthesia with slight hyperventilation (PCO2 33 mmHg)
Number of subjects: 20
Study 1787659 — intervention group
Group type: EXPERIMENTAL
Intervention: Halothane-nitrous oxide anesthesia with varying PCO2 levels
Number of subjects: 20
Study 7041769 — intervention group
Group type: EXPERIMENTAL
Intervention: New form of betahistine mesylate
Number of subjects: 0
Study 7041769 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 31183757 — intervention group
Group type: EXPERIMENTAL
Intervention: Education/training about pesticide use/adverse health effects in children
Number of subjects: 464
Study 31183757 — intervention group
Group type: COMPARATOR
Intervention: No education/training about pesticide use/adverse health effects in children
Number of subjects: 464
Study 31183757 — intervention group
Group type: COMPARATOR
Intervention: Grandparent as caregiver
Number of subjects: 464
Study 31183757 — intervention group
Group type: COMPARATOR
Intervention: Annual income < 297 USD
Number of subjects: 464
Study 31183757 — intervention group
Group type: COMPARATOR
Intervention: Insufficient health-related education/training
Number of subjects: 464
Study 28727654 — intervention group
Group type: EXPERIMENTAL
Intervention: nHMF
Number of subjects: 153
Study 28727654 — intervention group
Group type: COMPARATOR
Intervention: cHMF
Number of subjects: 153
Study 26470880 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise intervention for 12 weeks
Number of subjects: 120
Study 26470880 — intervention group
Group type: COMPARATOR
Intervention: Usual-care control group
Number of subjects: 120
Study 24171001 — intervention group
Group type: EXPERIMENTAL
Intervention: Uvulopalatopharyngoplasty (UPPP)
Number of subjects: 50
Study 24171001 — intervention group
Group type: COMPARATOR
Intervention: Nonsurgical group
Number of subjects: 50
Study 21371282 — intervention group
Group type: EXPERIMENTAL
Intervention: Antiplatelet therapy: 325 mg aspirin daily plus 75 mg clopidogrel daily
Number of subjects: 3000
Study 21371282 — intervention group
Group type: COMPARATOR
Intervention: Antiplatelet therapy: 325 mg aspirin daily plus placebo
Number of subjects: 3000
Study 21371282 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive systolic blood pressure target (<130 mmHg)
Number of subjects: 3000
Study 21371282 — intervention group
Group type: COMPARATOR
Intervention: Usual systolic blood pressure target (130-149 mmHg)
Number of subjects: 3000
Study 19621985 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin A (CsA) 5 mg/kg infused over 24 h
Number of subjects: 50
Study 19621985 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study 17997363 — intervention group
Group type: EXPERIMENTAL
Intervention: Open‐irrigation‐tip catheter
Number of subjects: 70
Study 17997363 — intervention group
Group type: COMPARATOR
Intervention: 8‐mm‐tip catheter
Number of subjects: 70
Study 15124801 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone (6 mg/kg BW, administered intravenously in six equal doses at 8 h intervals)
Number of subjects: 87
Study 15124801 — intervention group
Group type: COMPARATOR
Intervention: Placebo (control group)
Number of subjects: 87
Study 15124801 — intervention group
Group type: EXPERIMENTAL
Intervention: Methylprednisolone
Number of subjects: 87
Study 11786156 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS ≤16%
Number of subjects: 189
Study 11786156 — intervention group
Group type: COMPARATOR
Intervention: WMS >16%
Number of subjects: 189
Study 11786156 — intervention group
Group type: EXPERIMENTAL
Intervention: WMS ≤16% with ICD treatment
Number of subjects: 189
Study 9844306 — intervention group
Group type: EXPERIMENTAL
Intervention: Olfactometry using natural coffee, aniseed, lemon, and mint oils
Number of subjects: 73
Study 8271851 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate angioplasty
Number of subjects: 49
Study 8271851 — intervention group
Group type: COMPARATOR
Intervention: Thrombolysis followed by conservative therapy
Number of subjects: 49
Study 2574053 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol (50 mg twice daily)
Number of subjects: 0
Study 2574053 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (80 mg twice daily)
Number of subjects: 0
Study 2574053 — intervention group
Group type: COMPARATOR
Intervention: Metoprolol (100 mg twice daily)
Number of subjects: 0
Study 2574053 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2574053 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenytoin (100 mg intravenously)
Number of subjects: 0
Study 5298034 — intervention group
Group type: EXPERIMENTAL
Intervention: Ambilhar (non-metallic schistosomicide)
Number of subjects: 0
Study 31053622 — intervention group
Group type: EXPERIMENTAL
Intervention: Parental self-assessment of discharge readiness
Number of subjects: 0
Study 31053622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse assessment of family's emotional discharge readiness
Number of subjects: 0
Study 31053622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse assessment of family's technical discharge readiness
Number of subjects: 0
Study 31053622 — intervention group
Group type: EXPERIMENTAL
Intervention: Nurse familiarity with the family at discharge
Number of subjects: 0
Study 28284776 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 and 35 mg/kg GHB
Number of subjects: 47
Study 28284776 — intervention group
Group type: EXPERIMENTAL
Intervention: 35 mg/kg GHB
Number of subjects: 47
Study 28284776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 28284776 — intervention group
Group type: EXPERIMENTAL
Intervention: GHB
Number of subjects: 47
Study 26545298 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol
Number of subjects: 498
Study 26545298 — intervention group
Group type: EXPERIMENTAL
Intervention: Amisulpride
Number of subjects: 498
Study 26545298 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 498
Study 26545298 — intervention group
Group type: EXPERIMENTAL
Intervention: Quetiapine
Number of subjects: 498
Study 26545298 — intervention group
Group type: EXPERIMENTAL
Intervention: Ziprasidone
Number of subjects: 498
Study 23489776 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 200 μg/day
Number of subjects: 699
Study 23489776 — intervention group
Group type: EXPERIMENTAL
Intervention: Selenium 400 μg/day
Number of subjects: 699
Study 23489776 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 699
Study 21733952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (low-dose 100 mg/d)
Number of subjects: 47
Study 21733952 — intervention group
Group type: EXPERIMENTAL
Intervention: Cilostazol (high-dose 200 mg/d)
Number of subjects: 47
Study 21733952 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 19345784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized performance of procedures immediately after training
Number of subjects: 0
Study 19345784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized performance of procedures 1 year later
Number of subjects: 0
Study 19345784 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized performance of procedures 2 years later
Number of subjects: 0
Study 19345784 — intervention group
Group type: EXPERIMENTAL
Intervention: Scoring from routine participant testing and training
Number of subjects: 0
Study 16988754 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 100 mg + Amlodipine 5 mg
Number of subjects: 21
Study 16988754 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine 10 mg
Number of subjects: 21
Study 15180116 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise programme
Number of subjects: 30
Study 15180116 — intervention group
Group type: COMPARATOR
Intervention: Pulsed ultrasound
Number of subjects: 30
Study 15180116 — intervention group
Group type: COMPARATOR
Intervention: Transverse friction
Number of subjects: 30
Study 11192339 — intervention group
Group type: EXPERIMENTAL
Intervention: Preventive occupational therapy (OT) for 9 months
Number of subjects: 0
Study 9720932 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatic resection
Number of subjects: 123
Study 9720932 — intervention group
Group type: COMPARATOR
Intervention: Adjuvant chemotherapy
Number of subjects: 123
Study 9720932 — intervention group
Group type: COMPARATOR
Intervention: Intra-arterial infusion of doxorubicin
Number of subjects: 123
Study 7999406 — intervention group
Group type: EXPERIMENTAL
Intervention: naproxen 1500 mg
Number of subjects: 20
Study 7999406 — intervention group
Group type: COMPARATOR
Intervention: slow-release morphine 60 mg
Number of subjects: 20
Study 3213896 — intervention group
Group type: EXPERIMENTAL
Intervention: Buflomedil 600 mg.d-1 in association with anti-edema drugs
Number of subjects: 14
Study 3213896 — intervention group
Group type: COMPARATOR
Intervention: Anti-edema drugs only
Number of subjects: 14
Study 30274958 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based complaint-directed mini-interventions (CDMIs)
Number of subjects: 329
Study 30274958 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention, wait-listed)
Number of subjects: 329
Study 28666299 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 217
Study 28666299 — intervention group
Group type: EXPERIMENTAL
Intervention: Levofloxacin 500 mg
Number of subjects: 217
Study 28666299 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimethoprim 80 mg and Sulfamethoxazole 400 mg
Number of subjects: 217
Study 28666299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrofurantoin 100 mg
Number of subjects: 217
Study 26140500 — intervention group
Group type: EXPERIMENTAL
Intervention: Breath-stacking technique using a lung volume recruitment bag
Number of subjects: 40
Study 26140500 — intervention group
Group type: COMPARATOR
Intervention: Mechanical insufflator-exsufflator (MI-E)
Number of subjects: 40
Study 24262593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoverine (100 mg three times a day)
Number of subjects: 197
Study 24262593 — intervention group
Group type: COMPARATOR
Intervention: Trimebutine (150 mg three times a day)
Number of subjects: 197
Study 24262593 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenoverine
Number of subjects: 197
Study 24262593 — intervention group
Group type: COMPARATOR
Intervention: Trimebutine
Number of subjects: 197
Study 21175925 — intervention group
Group type: EXPERIMENTAL
Intervention: Access to the Northwestern University Rotating Resident Curriculum (NURRC) during the first 2 weeks of the rotation (experimental group)
Number of subjects: 54
Study 21175925 — intervention group
Group type: COMPARATOR
Intervention: No access to the NURRC during the first 2 weeks of the rotation (control group)
Number of subjects: 54
Study 21175925 — intervention group
Group type: EXPERIMENTAL
Intervention: NURRC access
Number of subjects: 54
Study 21175925 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with NURRC
Number of subjects: 54
Study 18509579 — intervention group
Group type: COMPARATOR
Intervention: Land-based exercise
Number of subjects: 79
Study 18509579 — intervention group
Group type: COMPARATOR
Intervention: Aquatic exercise
Number of subjects: 79
Study 18509579 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 79
Study 16548939 — intervention group
Group type: EXPERIMENTAL
Intervention: Maximal tailored behavioral treatment (baseline tailored brief motivational intervention, quit date behavioral skills counseling session, relapse prevention follow‐up session)
Number of subjects: 383
Study 16548939 — intervention group
Group type: COMPARATOR
Intervention: Minimal treatment (brief advice using the National Cancer Institute's 4 As model)
Number of subjects: 383
Study 14586916 — intervention group
Group type: EXPERIMENTAL
Intervention: Treadmill and overground walking program (30 minutes, 3 times a week for 4 weeks)
Number of subjects: 29
Study 14586916 — intervention group
Group type: COMPARATOR
Intervention: Placebo (low-intensity home exercise program and regular telephone contact)
Number of subjects: 29
Study 10342818 — intervention group
Group type: EXPERIMENTAL
Intervention: Aggressive cholesterol lowering
Number of subjects: 1351
Study 10342818 — intervention group
Group type: COMPARATOR
Intervention: Moderate cholesterol lowering
Number of subjects: 1351
Study 10342818 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose warfarin
Number of subjects: 1351
Study 10342818 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1351
Study 10342818 — intervention group
Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 1351
Study 10342818 — intervention group
Group type: COMPARATOR
Intervention: Nondiabetic patients
Number of subjects: 1351
Study 8728305 — intervention group
Group type: EXPERIMENTAL
Intervention: Atenolol 50 mg once daily
Number of subjects: 63
Study 8728305 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 10 mg once daily
Number of subjects: 63
Study 8728305 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine SR 20 mg twice daily
Number of subjects: 63
Study 8728305 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 2185865 — intervention group
Group type: EXPERIMENTAL
Intervention: 3F/wk radiotherapy
Number of subjects: 734
Study 2185865 — intervention group
Group type: COMPARATOR
Intervention: 5F/wk radiotherapy
Number of subjects: 734
Study 92897 — intervention group
Group type: EXPERIMENTAL
Intervention: Birch, alder and hazel allergen in Allpyral
Number of subjects: 47
Study 92897 — intervention group
Group type: EXPERIMENTAL
Intervention: Allpyral mixture plus all relevant tree pollens in aqueous extract
Number of subjects: 47
Study 92897 — intervention group
Group type: COMPARATOR
Intervention: No injections (Control group)
Number of subjects: 47
Study 92897 — intervention group
Group type: EXPERIMENTAL
Intervention: Immunotherapy (both treatment groups)
Number of subjects: 47
Study 31775650 — intervention group
Group type: COMPARATOR
Intervention: Care coordination intervention involving practical nurses trained to assess medication risks and coordinating with pharmacists and physicians.
Number of subjects: 129
Study 31775650 — intervention group
Group type: COMPARATOR
Intervention: Care coordination intervention
Number of subjects: 129
Study 28876274 — intervention group
Group type: EXPERIMENTAL
Intervention: Modern Ring External Fixators
Number of subjects: 0
Study 28876274 — intervention group
Group type: COMPARATOR
Intervention: Internal Fixation
Number of subjects: 0
Study 25119540 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.25 % levobupivacaine
Number of subjects: 55
Study 25119540 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (control)
Number of subjects: 55
Study 25098557 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal Protein (NP) breakfast (350 kcal, 13 g protein)
Number of subjects: 20
Study 25098557 — intervention group
Group type: EXPERIMENTAL
Intervention: High Protein (HP) breakfast (350 kcal, 35 g protein)
Number of subjects: 20
Study 25098557 — intervention group
Group type: COMPARATOR
Intervention: Breakfast Skipping (BS)
Number of subjects: 20
Study 21900837 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib
Number of subjects: 233
Study 21900837 — intervention group
Group type: COMPARATOR
Intervention: Carboplatin/paclitaxel
Number of subjects: 233
Study 21900837 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA EGFR mutation-positive subgroup
Number of subjects: 233
Study 21900837 — intervention group
Group type: EXPERIMENTAL
Intervention: cfDNA EGFR mutation-negative subgroup
Number of subjects: 233
Study 19909412 — intervention group
Group type: EXPERIMENTAL
Intervention: Buttonhole method of arteriovenous cannulation using the Biohole device
Number of subjects: 0
Study 17466735 — intervention group
Group type: EXPERIMENTAL
Intervention: Single dose of botulinum toxin type A (Botox) (200 or 300 U)
Number of subjects: 59
Study 17466735 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 59
Study 15983826 — intervention group
Group type: EXPERIMENTAL
Intervention: Aprepitant (125 mg on day 1, 80 mg on days 2 and 3)
Number of subjects: 22
Study 15983826 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 11997270 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral conjugated equine estrogen (0.625 mg/d)
Number of subjects: 264
Study 11997270 — intervention group
Group type: EXPERIMENTAL
Intervention: Estrogen plus progestin (medroxyprogesterone acetate 2.5 mg/d)
Number of subjects: 264
Study 11997270 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 264
Study 9806688 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.75% bupivacaine (1.5 mL)
Number of subjects: 50
Study 9806688 — intervention group
Group type: COMPARATOR
Intervention: 1% bupivacaine (1.125 mL)
Number of subjects: 50
Study 7714743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A (IPA/water/IPM; 11:7:1)
Number of subjects: 9
Study 7714743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B (ET/PG/IPM; 11:7:2)
Number of subjects: 9
Study 7714743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C (IPM/capmul)
Number of subjects: 9
Study 7714743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation A
Number of subjects: 9
Study 7714743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation B
Number of subjects: 9
Study 7714743 — intervention group
Group type: EXPERIMENTAL
Intervention: Formulation C
Number of subjects: 9
Study 3066620 — intervention group
Group type: EXPERIMENTAL
Intervention: Mazindol 2 mg
Number of subjects: 10
Study 3066620 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 29022227 — intervention group
Group type: EXPERIMENTAL
Intervention: Contribution to family support
Number of subjects: 226
Study 29022227 — intervention group
Group type: EXPERIMENTAL
Intervention: Predictors of contribution
Number of subjects: 226
Study 28682871 — intervention group
Group type: EXPERIMENTAL
Intervention: Enzalutamide (160 mg/d)
Number of subjects: 148
Study 28682871 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 148
Study 25627820 — intervention group
Group type: EXPERIMENTAL
Intervention: Goshajinkigan (GJG) 7.5 mg three times daily
Number of subjects: 182
Study 25627820 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 182
Study 21874353 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin analogues
Number of subjects: 47
Study 21874353 — intervention group
Group type: COMPARATOR
Intervention: Human insulin
Number of subjects: 47
Study 20709498 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous nicorandil (0.2 mg/kg/5 min bolus followed by continuous infusion at 0.05, 0.10, or 0.20 mg/kg/h for 6h)
Number of subjects: 0
Study 18166099 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 131
Study 18166099 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 131
Study 20845219 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing contextual interference practice schedule (initial blocked trials, followed by serial practice trials, and ended with random scheduling)
Number of subjects: 0
Study 20845219 — intervention group
Group type: EXPERIMENTAL
Intervention: Increasing contextual interference practice schedule (for basketball passes)
Number of subjects: 0
Study 20845219 — intervention group
Group type: COMPARATOR
Intervention: Blocked scheduling (control group for golf putting)
Number of subjects: 0
Study 20845219 — intervention group
Group type: COMPARATOR
Intervention: Random scheduling (control group for golf putting)
Number of subjects: 0